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Serum biomarkers of canine lymphoma activity for diagnosis, prognosis, and therapy 
monitoring have been of clinical interest for more than a decade. Tumor products, bio-
chemical enzymes, cytokines, metabolic profiling, leakage enzymes, as well as serum 
proteins have been studied as biomarkers for lymphoma. Multiple biomarkers combined 
have been shown to be most sensitive and specific. C-reactive protein, thymidine kinase 
1, and haptoglobin have been most extensively studied and commercialized in diagnostic 
tests, the TK Canine Cancer Panel and the Canine Lymphoma Blood Test. These tests 
have been evaluated either in cohorts of diseased and healthy dogs or in prospective 
studies of ill dogs, respectively, for application to clinical decision-making. Some evi-
dence exists for application of these tests, but large-scale studies are lacking in a broad 
range of lymphoma forms. These biomarkers are commonly elevated at diagnosis and at 
relapse. Further study is necessary to determine if early intervention guided by biomarker 
elevation will improve quantity or quality of life for dogs with lymphoma.
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inTRODUCTiOn
Serum biomarkers of lymphoma activity for diagnosis, prognosis, and therapy monitoring have been 
of clinical interest for more than a decade. There are opportunities to evaluate levels of natural 
serum constituents, tumor produced enzymes, or even nucleic acids released from tumors that may 
represent dysregulated tumor drivers. Such markers offer the challenge of sample stability for ship-
ping from remote sites, accurate and precise measurement of the diagnostic target, cross-reactivity 
of reagents in translation from human assays, sensitivity for the presence of lymphoma, and specific-
ity for lymphoma as a clinical disease entity distinct from other similar diseases. While the initial 
diagnosis requires tissue sampling, for clinical monitoring application, robust biomarkers must be 
associated with clinically relevant endpoints of definitive diagnosis separate from look-alike diseases, 
clinical remission with greater sensitivity for residual disease than manual palpation or other clinical 
evaluations, or progression of disease prior to clinically detectable evidence of that event.
Many targets have been investigated as serum biomarkers for canine lymphoma since the year 
2000. Tumor products alpha-fetoprotein (AFP) and microRNAs (1, 2); biochemical enzymes cor-
ticosteroid-induced alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) (3, 4); cytokine 
tumor necrosis factor-α (TNF-α) (5); metabolic profiling by gas chromatography (6); leakage enzymes 
thymidine kinase 1 (TK1) and high-mobility group B1 proteins (HMGB1) (7, 8); and fucosylated 
serum proteins as well as serum proteins serum amyloid A (SAA), C-reactive protein (CRP), and 
haptoglobin (9–13) have been evaluated. Targets were generally selected as tumor-specific products 
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or as participants in important disease-related pathways. Of the 
above candidates, only TK1, CRP, and haptoglobin have resulted 
in a commercially available biomarker test.
The focus of this review will be a brief examination of the 
recent biomarker candidates represented in the literature, the 
peer-reviewed support for application of those biomarkers dis-
cussing primarily TK1, CRP, and haptoglobin, and the evidence 
for clinical decision-making support published for these mol-
ecules. Most candidates have been evaluated for diagnosis and 
prognosis of lymphoma at the time of initial diagnosis. A few have 
been evaluated for monitoring remission as well. Application 
of biomarker monitoring to the heterogeneous disease of lym-
phoma, which varies by immunophenotype, histotype, anatomic 
location, and clinical aggressiveness, has been challenging. To 
date, large-scale clinical trials that would be necessary to define 
the role of biomarker evaluation in particular forms of lymphoma 
have not been conducted. The clinician is then left to evaluate the 
existing literature to determine appropriate clinical application 
of these tests.
TUMOR PRODUCTS
The tumor products AFP and microRNAs have been evaluated 
as potential diagnostic and prognostic biomarkers for lymphoma 
(1, 2). Synthesized in fetal tissue and neoplastic adult tissues, AFP 
elevations have been reported in dogs with hepatocellular carci-
noma and inflammatory/infiltrative diseases of the liver (14). Of 
the infiltrative diseases, some of the highest AFP levels were iden-
tified in dogs with hepatic lymphoma, which was then evaluated 
subsequently (1). When 63 dogs with lymphoma were compared 
to 80 normal controls, high-stage lymphoma dogs (27 stage III, 
15 stage IV, and 9 stage V) and male dogs had the highest average 
AFP serum levels (1). Over the course of chemotherapy, AFP 
levels were lower while the dogs were in remission. Prognostic 
value of this biomarker for survival was not evaluated. Serum 
levels of a panel of microRNAs were evaluated in 61 dogs with 
lymphoma (41 high-grade and 20 low-grade) (2). From the panel 
studied, levels of four miRNAs were reduced and one increased in 
the serum of dogs with lymphoma relative to healthy controls (2). 
Only two of the microRNAs distinguished high- vs. low-grade 
lymphoma, and few distinguished among anatomic locations 
of the disease (2). No attempt was made to apply the results to 
prognosis based on case outcome. While each of these approaches 
yielded statistically meaningful differences between lymphoma 
and healthy dogs, neither test has been used to distinguish ill dogs 
from dogs with lymphoma, and neither is currently commercially 
available as a diagnostic test.
BiOCHeMiCAL enZYMeS
The serum enzymes corticosteroid-induced ALP and LDH have 
been evaluated as biomarkers for lymphoma (3, 4). The enzyme 
ALP is derived from several potential sources in the body with 
the corticosteroid-induced isoform being present in ill dogs or 
following the endogenous production or exogenous administra-
tion of corticosteroids. Measurement of ALP in 62 dogs with 
lymphoma did not help predict response rate or duration of 
remission (3). The enzyme LDH is useful for prognosis of lym-
phoma in humans (3). It catalyzes the final step of glycolysis, an 
active metabolic pathway in canine lymphoma (4). In an evalu-
ation of 128 dogs with cancers compared to 211 ill dogs and 128 
healthy dogs, LDH levels were elevated in dogs with cancers, but 
the overlap was significant (4). Mean levels of LDH were highest 
in dogs with lymphoma among the examined cancers but did not 
distinguish among stage of lymphoma or help predict outcome 
(4). The conclusion of studies of both enzymes was that they were 
not useful clinical tools at this stage of development.
CYTOKineS AnD MeTABOLiC PRODUCTS
The cytokine TNF-α (5) and metabolic profiling by gas chroma-
tography (6) have been evaluated as biomarkers of lymphoma. 
Serum TNF-α was studied because the cytokine has been reported 
to be produced by malignant lymphoblasts. However, only 3 of 25 
dogs with lymphoma evaluated had detectable serum levels of 
the cytokine (5). Of the three with detectable levels, all became 
undetectable following therapy. However, the low frequency of 
detection led to the conclusion that TNF-α has limited value 
as a biomarker for lymphoma (5). Lymphoma is well known 
to alter body metabolism, so the serum metabolic profile of 21 
dogs with lymphoma was compared to 13 healthy dogs using gas 
chromatography (6). Using gas chromatography–mass spectrom-
etry analysis, 29 metabolites were used to differentiate between 
dogs with lymphoma and healthy controls with 16 metabolites 
having significantly different levels (6). Of three cases analyzed 
that entered complete remission after treatment, all three had 
metabolic profiles typical of the healthy dogs (6). The authors 
concluded that this metabolic approach could yield biomarkers 
of utility in monitoring lymphoma, but the analysis is not widely 
available for this application.
CeLLULAR LeAKAGe enZYMeS
Candidate cellular leakage enzymes evaluated as biomarkers 
include HMGB1 and TK1 (7, 8). The HMGB1 enzyme is generally 
an intracellular molecule that is released by damaged or dying 
cells; it can also be secreted by activated monocytes, macrophages, 
and astrocytes (8). A study of 16 dogs with lymphoma showed 
significantly elevated HMGB1 levels at diagnosis compared to 
normal dogs, although the ranges overlapped somewhat (8). 
Through the course of chemotherapy, HMGB1 levels diminished 
concurrent with the degree of perceived remission of disease. One 
dog with a partial remission retained higher levels than the dogs 
in complete remission (8). The authors concluded that because 
of this phenomenon, the enzyme may have value as a prognostic 
marker, but measurement is not currently available as a diagnos-
tic test. Thymidine kinase 1 (TK1) is a cytoplasmic enzyme that 
catalyzes the pyrimidine salvage pathway and is often expressed 
in neoplastic cells (7, 15). First reported in dogs in 2004, serum 
TK1 has been evaluated as a tool for both prognosis and disease 
monitoring of lymphoma (7). Utilizing a radio-enzyme assay, 
serum samples from 21 healthy beagles, 8 juvenile beagles, and 65 
dogs with lymphoma were evaluated for TK1 activity. The mean 
TK1 activity in the juvenile dogs was found to be higher than 
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the mean TK1 activity of the healthy adult dogs (7). Serum TK1 
activity in dogs with lymphoma was significantly higher than 
that of normal dogs or dogs with inflammation or other tumors 
(7). Evaluation with ROC analysis yielded a cut-point with a true 
positive rate of 92% and a false positive rate of only 1.9% (7). 
Further, serum TK1 activity was significantly higher in high-stage 
(≥stage 3 disease) than in low-stage lymphoma patients (7). 
Pretreatment serum TK1 activity above an arbitrary cut-point was 
prognostic, with high TK1 portending a much shorter survival, 
likely related to stage (7). A subsequent report confirmed that the 
early results could be recapitulated in a different population using 
a non-radiometric immunoassay with high correlation (16). This 
assay has shown promise as a biomarker of disease, prognosis, 
and monitoring (13, 17–19). The commercial application of this 
assay will be discussed subsequently.
SeRUM PROTeinS
Measurement of fucosylated serum proteins as well as SAA, CRP, 
and haptoglobin has been evaluated as biomarkers of lymphoma 
disease and treatment monitoring (9–13). A proteomic approach 
to analysis of glycosylation of serum proteins identified significant 
changes from normal in levels of 109 fucosylated peptides derived 
from serum proteins (11). Levels of 54 of these modified peptides 
changed from pretreatment to posttreatment measurement as 
well (11). Levels were seen to change at relapse, but the timing 
was not reported relative to clinical detection. The technique was 
concluded to offer potential for disease monitoring but has not 
been developed commercially. The acute phase protein SAA was 
elevated in dogs with lymphoma, decreased with therapy, but was 
not seen to elevate at relapse (10). The authors concluded that 
SAA was not a useful marker of relapse in dogs with lymphoma.
C-reactive protein has been evaluated by several groups as a 
biomarker of lymphoma activity. As a sole biomarker, serum CRP 
has been shown to be elevated at diagnosis in most dogs with 
lymphoma compared to healthy dogs, and to decrease to a range 
indistinguishable from healthy dogs when in remission (9, 20). 
The conclusion by the authors of both studies reported here was 
that CRP is not a useful biomarker for remission monitoring by 
itself. To that end, CRP has been evaluated in combination with 
another acute phase protein haptoglobin. A study of 16 dogs 
identified elevations of CRP, haptoglobin, or both in all 16 dogs 
(21). Elevations of CRP were generally of greater magnitude than 
those of haptoglobin. High-grade and advanced stages (most 
of the cases) had greater magnitude elevations. The authors 
were unable to evaluate the relationship of biomarker level to 
stage or prognosis because of the homogeneity of the cases in 
the study. Using a surface-enhanced laser desorption ionization 
time of flight (SELDI-TOF) protein detection method, another 
group identified CRP and haptoglobin as potential biomarkers 
of lymphoma and created ELISA-based assays for those proteins 
(12, 22). A bioinformatics approach was used to construct a 
model based on the two biomarkers to identify lymphoma cases 
to calculate a canine lymphoma blood test (cLBT) value (23). 
Evaluating 35 lymphoma samples and 34 control samples from 
non-lymphoma diseased dogs, a sensitivity of 91%, specificity 
of 88%, and accuracy of 89.9% was calculated for prediction at 
diagnosis (22). In a subsequent set of 96 dogs evaluated prospec-
tively with careful clinical follow-up, the test performed similarly 
with a sensitivity of 75%, specificity of 91%, and accuracy of 85% 
in initial diagnosis samples where 32 of the dogs were ultimately 
confirmed to have lymphoma (22). One caveat to these findings is 
that the reported values were calculated using 158 samples from 
96 dogs, so independence of the samples in the calculation may 
confound the result. The same group evaluated 57 dogs serially 
to determine the utility of this biomarker pair and algorithm in 
monitoring remission status and predicting relapse. Comparing 
clinical remission status to cLBT value, dogs in complete remis-
sion had significantly lower values than dogs at diagnosis or in 
partial remission or with progressive disease (12). Serum cLBT 
values at diagnosis and lowest value measured during therapy 
were associated with survival, with lowest values performing 
better (12). Falling serum cLBT levels lagged behind lymph node 
palpation for defining remission and rose prior to nodes enlarg-
ing in the dogs studied (12). Finally, serum CRP has also been 
evaluated in conjunction with TK1 with a calculated Neoplasia 
Index (NI) value resulting (13). Among 83 dogs with lymphoma 
evaluated, the NI was significantly elevated compared to controls 
(13). Dogs with T cell lymphoma had generally lower levels of 
TK1 (13). In this study, 16 of 156 control dogs had an NI in 
the middle to upper range, which would not be distinguishable 
from lymphoma (13). Follow-up of these dogs for monitoring of 
disease development was not reported.
COMMeRCiALiZATiOn
Currently, two tests are available commercially as serum 
biomarkers for lymphoma in dogs, the cLBT (Avacta Animal 
Health, Wetherby, UK) and the TK1 Canine Cancer Panel (NI) 
(VDI Laboratory, Simi Valley, CA, USA). Both laboratories have 
locations in the US for convenient shipping, and both offer clini-
cally useful turnaround time of results, typically within 1–3 days. 
Head-to-head comparison of the two testing methods for diag-
nostic support, prognostication, and remission monitoring has 
not been reported.
The cLBT has the advantage of literature that describes its use 
in the setting of initial diagnosis, prognostication, and remission 
monitoring (12, 22). Importantly, the computational background 
of the calculation of cLBT values has also been reported (23). 
Publication of this algorithm allows clinicians utilizing this test to 
assess the methods behind the analysis and provides a description 
of the ongoing machine learning built into the system (23). The 
cLBT was evaluated prospectively in cohorts of clinically ill dogs 
with performance similar to the unblinded comparison groups 
reported early in development of the test (12, 23). Prospective 
evaluation of cases in this manner is critical to understanding the 
real performance of such biomarker tests. Finally, the proprietors 
of the cLBT have reported prognostic data from prospectively 
collected cases as well, offering some understanding of the likely 
performance of the test (12). What is as yet unclear about the 
cLBT is how it performs across grades of lymphoma, whether the 
early detection of loss of remission will alter outcome for dogs 
with lymphoma, and whether the prognostic value of the test will 
hold up in larger populations of dogs with lymphoma.
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The NI calculation has the advantage of including not only 
CRP as a measure of systemic disease but also TK1, which is 
tumor-specific. Both these biomarkers are well described in 
literature but primarily evaluated in known cases (13, 17). The 
algorithm calculating the NI is only generally described and is 
specifically referred to as proprietary (13, 24). It is worth not-
ing that in one study of the NI in clinically healthy dogs, two 
dogs were prospectively identified as having elevated NI, which 
subsequently died of lymphoma (24). Overall, this study reported 
a sensitivity of the NI in dogs without disease for future disease 
development was 82% and the specificity 91%. The NI could dif-
ferentiate dogs developing cancer within 6 months with an ROC 
AUC of 0.93. This study reported significant differences in the 
ranges of CRP, TK1, and NI between dogs without cancer and 
those that developed cancer. However, the graphical representa-
tion of these ranges recorded a large number (>50) of values 
of both CRP and TK1 that were considered outliers (24). The 
methods did not describe whether these were included in the 
statistical comparison, but the box and whisker plot does not 
appear to reflect that they were (24). Each dog in the study that 
died of cancer had an elevated NI.
When considering whether to use a serum biomarker in 
lymphoma decision-making, a clinician must consider the state 
of knowledge of that test. The currently available commercial 
tests are relatively well described in the literature. The cLBT has 
been assessed prospectively in dogs of unknown initial diagnosis 
with similar disease presentations (12). The cLBT has also been 
reported to have prognostic significance in these prospective 
evaluations. What currently lacks for this test is an understanding 
of whether low-grade lymphomas have similarly elevated scores 
to high-grade lymphomas, whether prognosis of test score at the 
beginning and end of chemotherapy will remain prognostic in the 
broad patient population, and whether identifying early evidence 
of loss of remission before clinical node enlargement present will 
extend comfort or survival for these dogs. The NI calculation has 
the advantage of testing in a relatively broad range of cancers and 
a reasonable number of dogs with lymphoma. It also utilizes a 
biomarker that is a cytosolic leakage enzyme that may be more 
tumor-specific than only acute phase proteins. However, it has not 
yet been prospectively tested in a population of dogs with both 
lymphoma and similar disease presentations to understand how 
well it discriminates. It also appears that among a large number 
of apparently healthy dogs (n = 360), a relatively large proportion 
will have biomarker values higher than most of the population 
raising the possibility of false positives (24). Although both TK1 
and the NI track with remission status, it is not yet clear whether 
there is prognostic significance to the score, although level of TK1 
itself has been shown to be prognostic (7). As with any biomarker 
test, identification of early loss of remission is of unknown clinical 
benefit in dogs at this time.
COnCLUSiOn
Low-cost serum biomarkers for lymphoma diagnosis, prognosis, 
and disease monitoring are appealing clinical tools. The current 
literature contains some support for use of biomarkers in each 
of these applications. Commercially available tests are relatively 
sensitive to the presence of high-grade lymphoma in the body. 
No currently evaluated approaches have successfully separated 
indolent from aggressive lymphomas or immunophenotype 
of lymphoma. Utilizing genomic and epigenomic features may 
someday fill this gap. Further study is necessary to fully define 
the roles and accuracy of serum biomarker in the diagnosis and 
management of canine lymphoma.
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